US Patent Issued for Atlantic Healthcare’s Alicaforsen to Treat IBD Pouchitis

US Patent Issued for Atlantic Healthcare’s Alicaforsen to Treat IBD Pouchitis
A U.S. patent has been issued to Atlantic Healthcare’s investigational drug alicaforsen for the treatment of inflammatory bowel disease (IBD). The patent (No. 9453221) extends the use of alicaforsen in IBD-related rectal stump inflammation and pain, and is part of the trans-Atlantic group’s strategy to broaden the clinical indications and formulations based on alicaforsen. The therapy candidate is being evaluated

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *